Search
Jun 28
Spinal Cord Injury Investor Symposium: The CEO of Axonis Therapeutics discusses the importance of KCC2 inhibition in CNS disorders
Joanna Stanicka describes how Axonis is developing a small molecule that is KCC2-potentiating, with the idea to restore the role that...